• Je něco špatně v tomto záznamu ?

Effect of Erythropoietin, Iron Deficiency and Iron Overload on Liver Matriptase-2 (TMPRSS6) Protein Content in Mice and Rats

J. Frýdlová, P. Přikryl, J. Truksa, LL. Falke, X. Du, I. Gurieva, M. Vokurka, J. Krijt,

. 2016 ; 11 (2) : e0148540. [pub] 20160204

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16027694

Matriptase-2 (TMPRSS6) is an important negative regulator of hepcidin expression; however, the effects of iron overload or accelerated erythropoiesis on liver TMPRSS6 protein content in vivo are largely unknown. We determined TMPRSS6 protein content in plasma membrane-enriched fractions of liver homogenates by immunoblotting, using a commercial antibody raised against the catalytic domain of TMPRSS6. Plasma membrane-enriched fractions were obtained by centrifugation at 3000 g and washing. TMPRSS6 was detected in the 3000 g fraction as a 120 kDa full-length protein in both mice and rats. Feeding of iron-deficient diet as well as erythropoietin treatment increased TMPRSS6 protein content in rats and mice by a posttranscriptional mechanism; the increase in TMPRSS6 protein by erythropoietin was also observed in Bmp6-mutant mice. Administration of high doses of iron to mice (200, 350 and 700 mg/kg) decreased TMPRSS6 protein content. Hemojuvelin was detected in the plasma membrane-enriched fractions of control animals as a full length protein of approximately 52 kDa; in iron deficient animals, the full length protein was partially cleaved at the N-terminus, resulting in an additional weak band of approximately 47 kDa. In livers from hemojuvelin-mutant mice, TMPRSS6 protein content was strongly decreased, suggesting that intact hemojuvelin is necessary for stable TMPRSS6 expression in the membrane. Overall, the results demonstrate posttranscriptional regulation of liver TMPRSS6 protein by iron status and erythropoietin administration, and provide support for the interaction of TMPRSS6 and hemojuvelin proteins in vivo.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027694
003      
CZ-PrNML
005      
20161005132255.0
007      
ta
008      
161005s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0148540 $2 doi
024    7_
$a 10.1371/journal.pone.0148540 $2 doi
035    __
$a (PubMed)26845567
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Frýdlová, Jana $u Institute of Pathophysiology, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
245    10
$a Effect of Erythropoietin, Iron Deficiency and Iron Overload on Liver Matriptase-2 (TMPRSS6) Protein Content in Mice and Rats / $c J. Frýdlová, P. Přikryl, J. Truksa, LL. Falke, X. Du, I. Gurieva, M. Vokurka, J. Krijt,
520    9_
$a Matriptase-2 (TMPRSS6) is an important negative regulator of hepcidin expression; however, the effects of iron overload or accelerated erythropoiesis on liver TMPRSS6 protein content in vivo are largely unknown. We determined TMPRSS6 protein content in plasma membrane-enriched fractions of liver homogenates by immunoblotting, using a commercial antibody raised against the catalytic domain of TMPRSS6. Plasma membrane-enriched fractions were obtained by centrifugation at 3000 g and washing. TMPRSS6 was detected in the 3000 g fraction as a 120 kDa full-length protein in both mice and rats. Feeding of iron-deficient diet as well as erythropoietin treatment increased TMPRSS6 protein content in rats and mice by a posttranscriptional mechanism; the increase in TMPRSS6 protein by erythropoietin was also observed in Bmp6-mutant mice. Administration of high doses of iron to mice (200, 350 and 700 mg/kg) decreased TMPRSS6 protein content. Hemojuvelin was detected in the plasma membrane-enriched fractions of control animals as a full length protein of approximately 52 kDa; in iron deficient animals, the full length protein was partially cleaved at the N-terminus, resulting in an additional weak band of approximately 47 kDa. In livers from hemojuvelin-mutant mice, TMPRSS6 protein content was strongly decreased, suggesting that intact hemojuvelin is necessary for stable TMPRSS6 expression in the membrane. Overall, the results demonstrate posttranscriptional regulation of liver TMPRSS6 protein by iron status and erythropoietin administration, and provide support for the interaction of TMPRSS6 and hemojuvelin proteins in vivo.
650    _2
$a anemie z nedostatku železa $x metabolismus $7 D018798
650    _2
$a zvířata $7 D000818
650    _2
$a kostní morfogenetický protein 6 $x genetika $7 D055418
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a erythropoetin $x metabolismus $x farmakologie $7 D004921
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a železo $x metabolismus $7 D007501
650    _2
$a přetížení železem $x metabolismus $7 D019190
650    _2
$a játra $x účinky léků $x metabolismus $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a membránové proteiny $x metabolismus $7 D008565
650    _2
$a myši $7 D051379
650    _2
$a myši knockoutované $7 D018345
650    _2
$a mutace $7 D009154
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a serinové endopeptidasy $x metabolismus $7 D012697
650    _2
$a sodíko-draslíková ATPasa $x metabolismus $7 D000254
650    _2
$a deficit železa $7 D000090463
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Přikryl, Petr $u Institute of Pathophysiology, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Truksa, Jaroslav $u Institute of Biotechnology, Laboratory of Tumour Resistance, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Falke, Lucas L $u Department of Pathology, Kidney Group, University Medical Center Utrecht, Utrecht, the Netherlands.
700    1_
$a Du, Xin $u Division of Medical Genetics, Department of Medicine, University of California San Diego, La Jolla, California, United States of America.
700    1_
$a Gurieva, Iuliia $u Institute of Pathophysiology, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Vokurka, Martin $u Institute of Pathophysiology, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Krijt, Jan $u Institute of Pathophysiology, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 2 (2016), s. e0148540
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26845567 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161005132642 $b ABA008
999    __
$a ok $b bmc $g 1166008 $s 952324
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 2 $d e0148540 $e 20160204 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Možnosti archivace